Adiposopathy and thyroid disease: tracing the pathway to cardiovascular risk

References

• Bessesen DH. Update on obesity. J. Clin. Endocrinol. Metab. 93(6), 2027–2034 (2008).
   PubMed Web of Science ®Google Scholar
• Unger RH, Orci L. Lipoapoptosis: its mechanism and its diseases. Biochim. Biophys. Acta 1585(2–3), 202–212 (2002).
   PubMed Web of Science ®Google Scholar
• Drenick EJ, Bale GS, Seltzer F, Johnson DG. Excessive mortality and causes of death in morbidly obese men. JAMA 243(5), 443–445 (1980).
   PubMed Web of Science ®Google Scholar
• Roth J, Qiang X, Marbán SL, Redelt H, Lowell BC. The obesity pandemic: where have we been and where are we going? Obes. Res. 12(Suppl. 2), S88–S101 (2004).
   PubMedGoogle Scholar
• Ogden CL, Carroll MD, Flegal KM. Epidemiologic trends in overweight and obesity. Endocrinol. Metab. Clin. North Am. 32(4), 741–760, vii (2003).
   PubMed Web of Science ®Google Scholar
• Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J. Clin. Endocrinol. Metab. 94(6), 1853–1878 (2009).
   PubMed Web of Science ®Google Scholar
• Vague J. La différenciation sexuelle, facteur déterminant des formes de l’obésité. Presse Med. 30, 339–340 (1947).
   Google Scholar
• Bray GA, Glennon JA, Salans LB, Horton ES, Danforth E Jr, Sims EA. Spontaneous and experimental human obesity: effects of diet and adipose cell size on lipolysis and lipogenesis. Metab. Clin. Exp. 26(7), 739–747 (1977).
   PubMed Web of Science ®Google Scholar
• Halaas JL, Gajiwala KS, Maffei M et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269(5223), 543–546 (1995).
   PubMed Web of Science ®Google Scholar
• O’Rahilly S. Leptin: defining its role in humans by the clinical study of genetic disorders. Nutr. Rev. 60(10 Pt 2), S30–S34; discussion S68 (2002).
   Google Scholar
• Bays HE, González-Campoy JM, Henry RR et al.; Adiposopathy Working Group. Is adiposopathy (sick fat) an endocrine disease? Int. J. Clin. Pract. 62(10), 1474–1483 (2008).
   PubMed Web of Science ®Google Scholar
• Bays H, Abate N, Chandalia M. Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia. Future Cardiol. 1(1), 39–59 (2005).
   PubMedGoogle Scholar
• Bays HE. “Sick fat,” metabolic disease, and atherosclerosis. Am. J. Med. 122(Suppl. 1), S26–S37 (2009).
   PubMed Web of Science ®Google Scholar
• Danforth E Jr. The role of thyroid hormones and insulin in the regulation of energy metabolism. Am. J. Clin. Nutr. 38, 1006–1017 (1983).
   PubMed Web of Science ®Google Scholar
• Duntas L, Hauner H, Rosenthal J, Pfeiffer EF. Thyrotropin releasing hormone (TRH) immunoreactivity and thyroid function in obesity. Int. J. Obes. 15(1), 83–87 (1991).
   PubMedGoogle Scholar
• Taneichi H, Sasai T, Ohara M et al. Higher serum free triiodothyronine levels within the normal range are associated with metabolic syndrome components in Type 2 diabetic subjects with euthyroidism. Tohoku J. Exp. Med. 224(3), 173–178 (2011).
   PubMed Web of Science ®Google Scholar
• Alemany M. The defense of adipose tissue against excess substrate-induced hyperthrophia: immune system cell infiltration and arrested metabolic activity. J. Clin. Endocrinol. Metab. 96(1), 66–68 (2011).
   PubMed Web of Science ®Google Scholar
• Apovian CM, Bigornia S, Mott M et al. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler. Thromb. Vasc. Biol. 28(9), 1654–1659 (2008).
   PubMed Web of Science ®Google Scholar
• Wang B, Wood IS, Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch. 455(3), 479–492 (2007).
   PubMed Web of Science ®Google Scholar
• Heilbronn LK, Campbell LV. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr. Pharm. Des. 14(12), 1225–1230 (2008).
   PubMed Web of Science ®Google Scholar
• Nathan C. Epidemic inflammation: pondering obesity. Mol. Med. 14(7–8), 485–492 (2008).
   PubMed Web of Science ®Google Scholar
• Bays HE. Adiposopathy is “sick fat” a cardiovascular disease? J. Am. Coll. Cardiol. 57(25), 2461–2473 (2011).
   PubMed Web of Science ®Google Scholar
• Klimcáková E, Roussel B, Márquez-Quiñones A et al. Worsening of obesity and metabolic status yields similar molecular adaptations in human subcutaneous and visceral adipose tissue: decreased metabolism and increased immune response. J. Clin. Endocrinol. Metab. 96(1), E73–E82 (2011).
   PubMed Web of Science ®Google Scholar
• Obregon MJ. Thyroid hormone and adipocyte differentiation. Thyroid 18(2), 185–195 (2008).
   PubMed Web of Science ®Google Scholar
• Nomura E, Toyoda N, Harada A et al. Type 2 iodothyronine deiodinase is expressed in human preadipocytes. Thyroid 21(3), 305–310 (2011).
   PubMed Web of Science ®Google Scholar
• Calvo RM, Obregon MJ. Presence and regulation of D1 and D2 deiodinases in rat white adipose tissue. Metab. Clin. Exp. 60(9), 1207–1210 (2011).
   PubMed Web of Science ®Google Scholar
• López M, Varela L, Vázquez MJ et al. Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat. Med. 16(9), 1001–1008 (2010).
   PubMed Web of Science ®Google Scholar
• Jéquier E. Leptin signaling, adiposity, and energy balance. Ann. NY Acad. Sci. 967, 379–388 (2002).
   PubMed Web of Science ®Google Scholar
• Menendez C, Baldelli R, Camiña JP et al. TSH stimulates leptin secretion by a direct effect on adipocytes. J. Endocrinol. 176(1), 7–12 (2003).
   PubMed Web of Science ®Google Scholar
• Ravussin E, Smith SR. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and Type 2 diabetes mellitus. Ann. NY Acad. Sci. 967, 363–378 (2002).
   PubMed Web of Science ®Google Scholar
• Hsieh CJ, Wang PW, Wang ST et al. Serum leptin concentrations of patients with sequential thyroid function changes. Clin. Endocrinol. (Oxf.) 57(1), 29–34 (2002).
   PubMed Web of Science ®Google Scholar
• Ortega FJ, Jílková ZM, Moreno-Navarrete JM et al. Type I iodothyronine 5′-deiodinase mRNA and activity is increased in adipose tissue of obese subjects. Int. J. Obes. (Lond.) 36(2), 320–324 (2012).
   PubMed Web of Science ®Google Scholar
• al-Adsani H, Hoffer LJ, Silva JE. Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid hormone replacement. J. Clin. Endocrinol. Metab. 82(4), 1118–1125 (1997).
   PubMed Web of Science ®Google Scholar
• Kok P, Roelfsema F, Langendonk JG et al. High circulating thyrotropin levels in obese women are reduced after body weight loss induced by caloric restriction. J. Clin. Endocrinol. Metab. 90(8), 4659–4663 (2005).
   PubMed Web of Science ®Google Scholar
• Mantzoros CS, Magkos F, Brinkoetter M et al. Leptin in human physiology and pathophysiology. Am. J. Physiol. Endocrinol. Metab. 301(4), E567–E584 (2011).
   PubMed Web of Science ®Google Scholar
• Iacobellis G, Ribaudo MC, Zappaterreno A, Iannucci CV, Leonetti F. Relationship of thyroid function with body mass index, leptin, insulin sensitivity and adiponectin in euthyroid obese women. Clin. Endocrinol. (Oxf.) 62(4), 487–491 (2005).
   PubMed Web of Science ®Google Scholar
• Rotondi M, Leporati P, La Manna A et al. Raised serum TSH levels in patients with morbid obesity: is it enough to diagnose subclinical hypothyroidism? Eur. J. Endocrinol. 160(3), 403–408 (2009).
   PubMed Web of Science ®Google Scholar
• Reinehr T, de Sousa G, Andler W. Hyperthyrotropinemia in obese children is reversible after weight loss and is not related to lipids. J. Clin. Endocrinol. Metab. 91(8), 3088–3091 (2006).
   PubMed Web of Science ®Google Scholar
• Chikunguwo S, Brethauer S, Nirujogi V et al. Influence of obesity and surgical weight loss on thyroid hormone levels. Surg. Obes. Relat. Dis. 3(6), 631–635; discussion 635 (2007).
   PubMed Web of Science ®Google Scholar
• Taleb S, Herbin O, Ait-Oufella H et al. Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27(12), 2691–2698 (2007).
   PubMed Web of Science ®Google Scholar
• Mattioli B, Giordani L, Quaranta MG, Viora M. Leptin exerts an anti-apoptotic effect on human dendritic cells via the PI3K-Akt signaling pathway. FEBS Lett. 583(7), 1102–1106 (2009).
   PubMed Web of Science ®Google Scholar
• Paz-Filho GJ, Delibasi T, Erol HK, Wong ML, Licinio J. Cellular immunity before and after leptin replacement therapy. J. Pediatr. Endocrinol. Metab. 22(11), 1069–1074 (2009).
   PubMed Web of Science ®Google Scholar
• Dayspring TD, Pokrywka G. Impact of triglycerides on lipid and lipoprotein biology in women. Gend. Med. 7(3), 189–205 (2010).
   PubMedGoogle Scholar
• Brunzell JD. Dyslipidemia of the metabolic syndrome. In: Obesity. Mechanisms and Clinical Management. Eckel RH (Ed.). Lippincott Williams & Wilkins, PA, USA, 378–398 (2003).
   Google Scholar
• Duntas LH. Thyroid disease and lipids. Thyroid 12(4), 287–293 (2002).
   PubMed Web of Science ®Google Scholar
• Lopez D, Abisambra Socarrás JF, Bedi M, Ness GC. Activation of the hepatic LDL receptor promoter by thyroid hormone. Biochim. Biophys. Acta 1771(9), 1216–1225 (2007).
   PubMed Web of Science ®Google Scholar
• Sharma R, Sharma TK, Kaushik GG, Sharma S, Vardey SK, Sinha M. Subclinical hypothyroidism and its association with cardiovascular risk factors. Clin. Lab. 57(9–10), 719–724 (2011).
   PubMed Web of Science ®Google Scholar
• Mikhail GS, Alshammari SM, Alenezi MY, Mansour M, Khalil NA. Increased atherogenic low-density lipoprotein cholesterol in untreated subclinical hypothyroidism. Endocr. Pract. 14(5), 570–575 (2008).
   PubMedGoogle Scholar
• Lu L, Wang B, Shan Z et al. The correlation between thyrotropin and dyslipidemia in a population-based study. J. Korean Med. Sci. 26(2), 243–249 (2011).
   PubMed Web of Science ®Google Scholar
• Asvold BO, Bjøro T, Nilsen TI, Vatten LJ. Association between blood pressure and serum thyroid-stimulating hormone concentration within the reference range: a population-based study. J. Clin. Endocrinol. Metab. 92(3), 841–845 (2007).
   PubMed Web of Science ®Google Scholar
• Samaranayake NR, Ong KL, Leung RY et al. Management of obesity in the National Health and Nutrition Examination Survey (NHANES), 2007–2008. Ann. Epidemiol. 22(5), 349–353 (2012).
   PubMed Web of Science ®Google Scholar
• Williams PT, Krauss RM, Stefanick ML, Vranizan KM, Wood PD. Effects of low-fat diet, calorie restriction, and running on lipoprotein subfraction concentrations in moderately overweight men. Metab. Clin. Exp. 43(5), 655–663 (1994).
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Lindström J, Eriksson JG et al.; Finnish Diabetes Prevention Study Group. Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344(18), 1343–1350 (2001).
   PubMed Web of Science ®Google Scholar
• Wadden TA, Volger S, Sarwer DB et al. A two-year randomized trial of obesity treatment in primary care practice. N. Engl. J. Med. 365(21), 1969–1979 (2011).
   PubMed Web of Science ®Google Scholar
• Bays HE. Lorcaserin and adiposopathy: 5-HT2C agonism as a treatment for ‘sick fat’ and metabolic disease. Expert Rev. Cardiovasc. Ther. 7(11), 1429–1445 (2009).
   PubMedGoogle Scholar
• Tam CS, Lecoultre V, Ravussin E. Novel strategy for the use of leptin for obesity therapy. Expert Opin. Biol. Ther. 11(12), 1677–1685 (2011).
   PubMed Web of Science ®Google Scholar
• Tancevski I, Rudling M, Eller P. Thyromimetics: a journey from bench to bed-side. Pharmacol. Ther. 131(1), 33–39 (2011).
   PubMed Web of Science ®Google Scholar
• Ladenson PW, Kristensen JD, Ridgway EC et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N. Engl. J. Med. 362(10), 906–916 (2010).
   PubMed Web of Science ®Google Scholar
• Tancevski I, Demetz E, Eller P. Sobetirome: a selective thyromimetic for the treatment of dyslipidemia. Recent Pat. Cardiovasc. Drug Discov. 6(1), 16–19 (2011).
   PubMedGoogle Scholar
• Scanlan TS. Sobetirome: a case history of bench-to-clinic drug discovery and development. Heart Fail. Rev. 15(2), 177–182 (2010).
   PubMed Web of Science ®Google Scholar
• Appachi S, Kelly KR, Schauer PR et al. Reduced cardiovascular risk following bariatric surgeries is related to a partial recovery from “adiposopathy”. Obes. Surg. 21(12), 1928–1936 (2011).
   PubMed Web of Science ®Google Scholar